Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
Jane D. Mount, Roland W. Herzog, David Michael Tillson et al. · Blood · 2002
Hemophilia B is an X-linked coagulopathy caused by absence of functional coagulation factor IX (FIX). Using adeno-associated virus (AAV)-mediated, liver-directed gene therapy, we achieved long-term (> 17 months) substantial correction of canine hemophilia B in 3 of 4 animals, including 2 dogs with an FIX null mutation. This was accomplished with a comparatively low dose of 1 x 10(12) vector genomes/kg. Canine FIX (cFIX) levels rose to 5% to 12% of normal, high enough to result in nearly complete phenotypic correction of the disease. Activated clotting times and whole blood clotting times were normalized, activated partial thromboplastin times were substantially reduced, and anti-cFIX was not detected. The fourth animal, also a null mutation dog, showed transient expression (4 weeks), but subsequently developed neutralizing anti-cFIX (inhibitor). Previous work in the canine null mutation model has invariably resulted in inhibitor formation following treatment by either gene or protein replacement therapies. This study demonstrates that hepatic AAV gene transfer can result in sustained therapeutic expression in a large animal model characterized by increased risk of a neutralizing anti-FIX response.
Cited by 339 works. doi:10.1182/blood.v99.8.2670
Authors
- Jane D. Mount
- Roland W. Herzog
- David Michael Tillson
- Susan A. Goodman
- Nancy A. Robinson
- Mark L. McCleland
- Dwight A. Bellinger
- Timothy C. Nichols
- Valder R. Arruda
- Clinton D. Lothrop
- Katherine A. High
References
- Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
- Oral tolerance: immune mechanisms and treatment of autoimmune diseases
- Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
- Adeno-associated virus vectors can be efficiently produced without helper virus
- Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
- Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance
- In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs
- In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
- Local control of the immune response in the liver